Cross-reactivity reduced dengue virus serotype 2 vaccine does not confer cross-protection against other serotypes of dengue viruses
J. U. Galula, C.-Y. Yang, B. S. Davis, G.-J. J. Chang, D.-Y. Chao
This study evaluates a cross-reactivity reduced DENV-2 vaccine and finds it provides partial protection against heterologous DENV-3 challenge but requires a multivalent format for broad protection.
Future Virology · Mar 23, 2020Peer-reviewedImmunology